WO2001070203A2 - Mittel zur behandlung von hepatitis c, enthaltend ukrain - Google Patents
Mittel zur behandlung von hepatitis c, enthaltend ukrain Download PDFInfo
- Publication number
- WO2001070203A2 WO2001070203A2 PCT/AT2001/000076 AT0100076W WO0170203A2 WO 2001070203 A2 WO2001070203 A2 WO 2001070203A2 AT 0100076 W AT0100076 W AT 0100076W WO 0170203 A2 WO0170203 A2 WO 0170203A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ukrain
- patients
- ifn
- hepatitis
- doses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Definitions
- the present invention relates to the use of phosphorus derivatives of alkaloids for the manufacture of a medicament for the treatment of hepatitis C.
- hepatitis C means a disease that has only been researched for a relatively short time. For a long time it was only known that there is a disease here that causes symptoms similar to the hepatitis A and hepatitis B diseases known to date, but that there are certain significant differences in the form of the disease. For a long time, the disease was therefore characterized as "hepatitis non-A non-B".
- Hepatitis C is a disease that is particularly prevalent in underdeveloped countries; It is believed that around 170 million people worldwide (i.e. approximately 4 times the amount of HIV infections) are infected with hepatitis C.
- AT 377 988 B and AT 354 644 B describe processes for the preparation of new phosphorus derivatives of alkaloids or of new salts of alkaloid derivatives of thiophosphoric acid. Such compounds have pharmacological activity and can be used as cytostatics.
- the object of the present invention is therefore the use of the reaction product of the alkaloids of Chelidonium majus L. with thiophosphoric acid triaziridide for the manufacture of a medicament for combating hepatitis C.
- Ukrain The above-mentioned implementation product will be briefly referred to below as "Ukrain"; the overwhelming majority of Ukrain has the following formula:
- IFN was tested in doses of 20, 50, 100, 200, 400, 600, 1000 IU / l blood, Ukrain in doses of 0.05, 0.1, 0.2, 0.5, 1.0 and 2, 0 ⁇ g / ml blood.
- Ten of the CHC patients examined were selected for the clinical Pilot trial with individual optimal IFN doses (0.5 to 2.0 ME (unit of measure) per injection, 6 patients, including 3 cases of HCV phenotype la) three times a week and Ukrain doses (0.25 to 2.5 mg per injection, 4 patients, including 2 HCV lb cases) every other day.
- the responses to the two compositions were shown to be different: 52.5% of all patients were sensitive to IFN and 73.1% to Ukrain, with the increase in the SH / SS ratio under the influence of the compositions being positive Effect and the reduction was assessed as a negative effect. Some patients have already shown a positive effect on the first dose of the preparations, others only on two or more doses.
- the optimal biological response to IFN in doses of 400, 200 and 100 IU / ml blood and to Ukrain in doses of 0.5, 0.1 and 0.2 ⁇ g / l blood was recorded more frequently.
- Standardized therapeutic IFN doses of 600 to 1000 IU / ml which correspond to in vivo injections of 3.0 to 5.0 ME doses, only showed a positive effect on the SH / SS system in 0 to 18.2% of the cases and a negative effect in 63.6 to 81.8% of cases, which is one of the reasons for the low effectiveness of IFN in CHC and the frequency of side effects in IFN therapy.
- 9 out of 10 patients were HCV-RNA negative in PCR: 3 after one month, 3 after three months of therapy with an individual IFN dose, 3 after three weeks of individual therapy with Ukrain. No serious side effects have been identified and treatment of all patients is ongoing.
- the response to Ukrain was shown to be different: 73.1% of all patients were sensitive to this composition, while in the same group of CHC patients, sensitivity to interferon-alpha 2b (IFN) was significantly lower, namely 46 2%. In the group of CHC patients who were IFN-resistant, the sensitivity to Ukrain was almost the same (71.4%). Furthermore, all 4 CHC patients with HCV phenotype lb were sensitive to Ukrain in vitro. The optimal biological response to Ukrain doses of 0.5, 0.1 and 0.2 ⁇ g / ml blood was frequently recorded.
- IFN interferon-alpha 2b
- the medicaments produced according to the invention preferably consist of an aqueous solution of the alkaloid phosphor derivatives or their salts used, optionally together with other auxiliaries known per se.
- the medicament according to the invention is preferably administered by injection, for example intraperitoneally, intramuscularly or intravenously, the dosage depending on the case and being related to the severity of the disease to be treated and the condition of the patient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020027005739A KR20020087045A (ko) | 2000-03-22 | 2001-03-20 | C형 간염 치료제 |
PL01365000A PL365000A1 (en) | 2000-03-22 | 2001-03-20 | Agent for treating hepatitis c containing ukrain |
EA200200584A EA200200584A1 (ru) | 2000-03-22 | 2001-03-20 | Средство для лечения гепатита c |
AU2001239000A AU2001239000A1 (en) | 2000-03-22 | 2001-03-20 | Agent for treating hepatitis C containing Ukrain |
CA002389173A CA2389173A1 (en) | 2000-03-22 | 2001-03-20 | Agent for treating hepatitis c |
BR0107211-0A BR0107211A (pt) | 2000-03-22 | 2001-03-20 | Agente para tratar hepatite c |
IL14931401A IL149314A0 (en) | 2000-03-22 | 2001-03-20 | Agent for treating hepatitis c |
JP2001568401A JP2003527414A (ja) | 2000-03-22 | 2001-03-20 | C型肝炎を治療するための薬剤 |
MXPA02004993A MXPA02004993A (es) | 2000-03-22 | 2001-03-20 | Medicamento para el tratramiento de hepatitis c. |
IS6360A IS6360A (is) | 2000-03-22 | 2002-04-24 | Lyf til meðhöndlunar á lifrarbólgu C |
HR20020367A HRP20020367A2 (en) | 2000-03-22 | 2002-04-26 | Agent for treating hepatitis c |
NO20022253A NO20022253D0 (no) | 2000-03-22 | 2002-05-10 | Middel til behandling av hepatitt C |
BG107088A BG107088A (en) | 2000-03-22 | 2002-09-12 | Agent for treating hepatitis c |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA481/2000 | 2000-03-22 | ||
AT0048100A AT408719B (de) | 2000-03-22 | 2000-03-22 | Mittel zur behandlung von hepatitis c |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001070203A2 true WO2001070203A2 (de) | 2001-09-27 |
WO2001070203A3 WO2001070203A3 (de) | 2002-09-06 |
Family
ID=3674939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AT2001/000076 WO2001070203A2 (de) | 2000-03-22 | 2001-03-20 | Mittel zur behandlung von hepatitis c, enthaltend ukrain |
Country Status (17)
Country | Link |
---|---|
JP (1) | JP2003527414A (zh) |
KR (1) | KR20020087045A (zh) |
CN (1) | CN1416347A (zh) |
AT (1) | AT408719B (zh) |
AU (1) | AU2001239000A1 (zh) |
BG (1) | BG107088A (zh) |
BR (1) | BR0107211A (zh) |
CA (1) | CA2389173A1 (zh) |
EA (1) | EA200200584A1 (zh) |
HR (1) | HRP20020367A2 (zh) |
IL (1) | IL149314A0 (zh) |
IS (1) | IS6360A (zh) |
MA (1) | MA25509A1 (zh) |
MX (1) | MXPA02004993A (zh) |
NO (1) | NO20022253D0 (zh) |
PL (1) | PL365000A1 (zh) |
WO (1) | WO2001070203A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003041721A1 (en) * | 2001-11-15 | 2003-05-22 | Nowicky Wassili | Process for reacting alkaloids and use of the reaction products in the preparation of medicaments |
EP2083825A1 (en) * | 2006-09-26 | 2009-08-05 | Addiction Research Institute, INC. | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c |
US7795434B2 (en) | 2003-03-18 | 2010-09-14 | Wassyl Nowicky | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106343303A (zh) * | 2015-07-13 | 2017-01-25 | 张如安 | 灭杀乙肝病毒的饮料 |
CN106109538A (zh) * | 2016-07-29 | 2016-11-16 | 桂林淮安天然保健品开发有限公司 | 治疗丙肝的药物组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0393575A1 (en) * | 1989-04-17 | 1990-10-24 | G.D. Searle & Co. | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3128018A1 (de) * | 1981-07-13 | 1983-04-07 | Wassyl 1060 Wien Nowicky | "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze" |
US4970212A (en) * | 1982-05-18 | 1990-11-13 | Nowicky Wassili | Method of treating human illnesses which compromise the ability to mount an effective immunological response |
US4816462A (en) * | 1982-05-18 | 1989-03-28 | Nowicky Wassili | Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds |
-
2000
- 2000-03-22 AT AT0048100A patent/AT408719B/de not_active IP Right Cessation
-
2001
- 2001-03-20 CA CA002389173A patent/CA2389173A1/en not_active Abandoned
- 2001-03-20 WO PCT/AT2001/000076 patent/WO2001070203A2/de active Application Filing
- 2001-03-20 BR BR0107211-0A patent/BR0107211A/pt not_active IP Right Cessation
- 2001-03-20 PL PL01365000A patent/PL365000A1/xx not_active Application Discontinuation
- 2001-03-20 JP JP2001568401A patent/JP2003527414A/ja active Pending
- 2001-03-20 AU AU2001239000A patent/AU2001239000A1/en not_active Abandoned
- 2001-03-20 IL IL14931401A patent/IL149314A0/xx unknown
- 2001-03-20 EA EA200200584A patent/EA200200584A1/ru unknown
- 2001-03-20 CN CN01803046A patent/CN1416347A/zh active Pending
- 2001-03-20 KR KR1020027005739A patent/KR20020087045A/ko not_active Application Discontinuation
- 2001-03-20 MX MXPA02004993A patent/MXPA02004993A/es unknown
-
2002
- 2002-04-24 IS IS6360A patent/IS6360A/is unknown
- 2002-04-26 HR HR20020367A patent/HRP20020367A2/hr not_active Application Discontinuation
- 2002-05-10 NO NO20022253A patent/NO20022253D0/no unknown
- 2002-05-28 MA MA26657A patent/MA25509A1/fr unknown
- 2002-09-12 BG BG107088A patent/BG107088A/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0393575A1 (en) * | 1989-04-17 | 1990-10-24 | G.D. Searle & Co. | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent |
Non-Patent Citations (1)
Title |
---|
I. VOLTCHEK, T. SOLOGUB ET AL.: "Choice for ukrain and interferon-alpha doses for the cancer patients therapy" EJC, Bd. 35, Nr. 5, Oktober 1999 (1999-10), Seite s20 XP002197747 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003041721A1 (en) * | 2001-11-15 | 2003-05-22 | Nowicky Wassili | Process for reacting alkaloids and use of the reaction products in the preparation of medicaments |
JP2005509006A (ja) * | 2001-11-15 | 2005-04-07 | ノヴィッキイ、 ヴァジル | アルカロイドを反応させる製造方法および反応生成物の薬剤調製の使用 |
CN100436462C (zh) * | 2001-11-15 | 2008-11-26 | 挪威奇·华兹 | 生物碱的反应方法、反应产物及其应用 |
US7795434B2 (en) | 2003-03-18 | 2010-09-14 | Wassyl Nowicky | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments |
EP2083825A1 (en) * | 2006-09-26 | 2009-08-05 | Addiction Research Institute, INC. | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c |
EP2083825A4 (en) * | 2006-09-26 | 2009-11-04 | Addiction Res Inst Inc | HEPATITIS C TREATMENT COMPOSITIONS AND METHODS OF USING HEPATITIS C TREATMENT COMPOSITIONS |
Also Published As
Publication number | Publication date |
---|---|
PL365000A1 (en) | 2004-12-27 |
MXPA02004993A (es) | 2003-10-14 |
IS6360A (is) | 2002-04-24 |
KR20020087045A (ko) | 2002-11-21 |
ATA4812000A (de) | 2001-07-15 |
NO20022253L (no) | 2002-05-10 |
JP2003527414A (ja) | 2003-09-16 |
WO2001070203A3 (de) | 2002-09-06 |
HRP20020367A2 (en) | 2004-02-29 |
IL149314A0 (en) | 2002-11-10 |
AU2001239000A1 (en) | 2001-10-03 |
MA25509A1 (fr) | 2002-07-01 |
NO20022253D0 (no) | 2002-05-10 |
BG107088A (en) | 2003-05-30 |
AT408719B (de) | 2002-02-25 |
EA200200584A1 (ru) | 2003-06-26 |
BR0107211A (pt) | 2004-01-06 |
CN1416347A (zh) | 2003-05-07 |
CA2389173A1 (en) | 2001-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0065747B1 (de) | Nonapeptid zur Behandlung von Suchtmittelentzugserscheinungen | |
DE2832204A1 (de) | Mittel zur behandlung von nervenerkrankungen, verfahren zu seiner herstellung und seine verwendung | |
DE2404416A1 (de) | Neurotropisch wirksames mittel und verfahren zu seiner herstellung | |
DE69821498T2 (de) | Verwendung von amifostin | |
DE3390419T1 (de) | Arzneimittel zur Behandlung der Ulkuskrankheit | |
EP0236951A2 (de) | Verwendung von Diphenylhydantoin und seinen Derivaten zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Immunerkrankungen | |
DE69830154T2 (de) | Pharmazeutische zusammensetzungen | |
AT408719B (de) | Mittel zur behandlung von hepatitis c | |
DE69911350T2 (de) | Vorbeugung und behandlung einer durch einen immunschwächevirus ausgelösten infektion | |
DE2206570B2 (de) | Verwendung von ( + ) - Catechin | |
EP0607777A2 (de) | Verwendung von Leflunomid zur Herstellung von Interleukin 8 | |
EP0132595B1 (de) | Tokolytisches Mittel | |
DE2325070A1 (de) | Pharmazeutische zubereitungen zur prophylaxe und zur behandlung von kapillarvenoesen erkrankungen | |
DE2528460A1 (de) | Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans | |
DE3141970C2 (zh) | ||
DE4329857C2 (de) | Verbindung zur Stärkung des Immunsystems und von Immunreaktionen | |
DE3542165A1 (de) | Medikament zur behandlung des syndroms der erworbenen immunschwaeche (aids) und entsprechende pharmazeutische zusammensetzungen | |
DE3821392A1 (de) | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen) | |
DE3424279A1 (de) | Verwendung von mini-somatostatinen fuer die behandlung der senilen demenz | |
DE69828526T2 (de) | Mittel gegen leishmaniasis, enthaltend glucopyrnosederivat als aktiven inhaltsstoff | |
EP1492546B1 (de) | Verwendung von pyrimidinnukleotiden zur behandlung von schaedigungen des peripheren nervensystems | |
DE2518509B2 (de) | Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin | |
EP1528922B1 (de) | Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose | |
DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen | |
DE19711795C2 (de) | Verwendung von Cyclosporin für die Behandlung von Myokardinfarkten und deren Folgen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref document number: 2001 106629 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 149314 Country of ref document: IL Ref document number: 518582 Country of ref document: NZ Ref document number: 200203266 Country of ref document: ZA Ref document number: 1200200365 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20020367A Country of ref document: HR Ref document number: 2389173 Country of ref document: CA Ref document number: IN/PCT/2002/00431/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-1502 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2001 568401 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6152002 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027005739 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/004993 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018030467 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200200584 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2001 107088 Country of ref document: BG Kind code of ref document: A |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2002-1502 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 20020643 Country of ref document: UZ Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001239000 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2001 9053 Country of ref document: AT Date of ref document: 20010927 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20019053 Country of ref document: AT |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027005739 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |